Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases
The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from Myrica cerifera , and is in about 86% enantiomeric excess of (−)-αS,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.
1. A method of preparing a Myrica extract comprising myricanol, comprising:
a) providing a sufficient quantity of raw material of a Myrica species;
b) extracting the raw material with toluene to yield a toluene fraction and a first residue;
c) mixing the first residue with ethanol to yield an ethanol fraction and a second residue;
d) mixing the second residue with CMT buffer comprising about 30% chloroform, 10% methanol and 0.002% trifluoroacetic acid (TFA) to obtained a CMT extract; and
e) fractionating the CMT extract using MPLC and recovering the fraction that comprises myricanol.
2. The method of claim 1 , wherein the myricanol is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol, wherein the (±)-αR,11S form is in at least 10% enantiomeric excess of the (−)-αS,11R foam.
3. The method of claim 2 , wherein the (+)-αR,11S form is in about 86% enantiomeric excess of the (−)-αS,11R form.